"Interleukin-23" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-23 is comprised of a unique 19 kDa subunit and 40 kDa subunit that is shared with INTERLEUKIN-12. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells
| Descriptor ID |
D053759
|
| MeSH Number(s) |
D12.644.276.374.465.759 D12.776.467.374.465.759 D23.529.374.465.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-23".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-23".
This graph shows the total number of publications written about "Interleukin-23" by people in this website by year, and whether "Interleukin-23" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 5 | 5 | 10 |
| 2018 | 7 | 9 | 16 |
| 2019 | 1 | 3 | 4 |
| 2020 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-23" by people in Profiles.
-
Management of Crohn's disease in an immunosuppressed COVID-19-positive patient: safety-driven prioritisation of nutritional therapy as a bridge to restarting immunosuppression. BMJ Case Rep. 2021 Mar 22; 14(3).
-
T Helper 17 Response to Severe Acute Respiratory Syndrome Coronavirus 2: A Type of Immune Response with Possible Therapeutic Implications. Viral Immunol. 2021 04; 34(3):190-200.
-
COVID-19 infection on IL-23 inhibition. Dermatol Ther. 2020 11; 33(6):e13893.
-
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic. Dermatol Ther. 2020 09; 33(5):e13687.
-
SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol. 2020 Jun; 34(6):e254-e255.
-
Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient. J Eur Acad Dermatol Venereol. 2020 Aug; 34(8):e363-e364.
-
The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020 05; 8(1).
-
CD109 Restrains Activation of Cutaneous IL-17-Producing ?d T Cells by Commensal Microbiota. Cell Rep. 2019 10 08; 29(2):391-405.e5.
-
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease. J Dermatolog Treat. 2021 Mar; 32(2):261-263.
-
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019 03; 16(3):185-196.